Effects of meiosis-inhibiting agents and equine chorionic gonadotropin on nuclear maturation of canine oocytes.
Experiments were conducted to determine the effects of meiosis-inhibiting-agents and gonadotropins on nuclear maturation of canine oocytes. The culture medium was TCM199 + 10 ng/ml epidermal growth factor supplemented with 25 microM beta-mercaptoethanol, 0.25 mM pyruvate, and 1.0 mM L-glutamine (Basal TCM). Initially, oocytes were cultured in Basal TCM alone or in Basal TCM + dibutylryl cyclic adenosine monophosphate (0.5, 1, 5, or 10 mM dbcAMP) for 24 hr. Dibutylryl cAMP inhibited resumption of meiosis in a dose-dependent manner; 60% of oocytes remained at the germinal vesicle (GV) stage after being cultured for 24 hr in 5 mM dbcAMP. The meiosis-inhibitory effect of dbcAMP appeared to be reversible, as the oocytes resumed meiosis and completed nuclear maturation after being cultured for an additional 48 hr in its absence. Oocytes were then cultured in Basal TCM alone or in Basal TCM + roscovitine (12.5, 25, or 50 microM) for 24 hr. Although approximately 60% of oocytes cultured in 25 microM roscovitine remained at the GV stage, this percentage was not significantly different from the 48% that also remained at the GV stage when cultured in its absence. Oocytes were cultured in Basal TCM + 25 microM roscovitine for 17 hr, exposed briefly to equine chorionic gonadotropin (eCG), and then cultured in Basal TCM for 48 hr. Short exposure of oocytes to eCG was beneficial, as it significantly increased the proportion of oocytes developing beyond germinal vesicle breakdown (P < 0.05) with approximately 20-30% of these were metaphase I (MI) oocytes. Study of the kinetics of nuclear maturation demonstrated that large numbers of oocytes remained at MI even after being cultured for 52 hr following brief exposure to eCG. This study showed that in vitro maturation of canine oocytes can be somewhat improved by short exposure of oocytes to eCG. However, further studies are still required to derive effective methods to mature canine oocytes in vitro.
Songsasen
N
N
Department of Biological Sciences, University of New Orleans, New Orleans, Louisiana. songsassenn@crc.si.edu
Yu
I
I
Gomez
M
M
Leibo
S P
SP
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology*; D002467:Cell Nucleus / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology*; D013006:Growth Hormone / Q000378:metabolism; D007986:Luteinizing Hormone / Q000378:metabolism; D008540:Meiosis / Q000187:drug effects* / Q000502:physiology; D008623:Mercaptoethanol / Q000378:metabolism; D015877:Miosis / Q000378:metabolism; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development*; D009866:Oogenesis / Q000187:drug effects; D011687:Purines / Q000494:pharmacology*; D000077546:Roscovitine
D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D011687:Purines; D000077546:Roscovitine; D008623:Mercaptoethanol; D003994:Bucladesine; D007986:Luteinizing Hormone; D013006:Growth Hormone